Merck & Co Inc is to acquire Imago BioSciences Inc, a clinical-stage biopharmaceutical company, for $36 per share in cash in order to strengthen its presence in haematology. The deal, valued at $1.35 billion, is expected to close in the first quarter of 2023. It will be one of the first big transactions executed by the company’s new chief executive Robert Davis, who has succeeded Kenneth Frazier.
